ReviewFrontiers in oncology2026
ERCC6L in human cancers: oncogenic functions, molecular mechanisms, and clinical implications as a prognostic biomarker and therapeutic target.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Excision repair cross-complementation group 6-like (ERCC6L), also known as PICH, is a centromere-associated SNF2 family ATPase that functions as a DNA helicase essential for mitotic chromosome segregation. Emerging evidence has established its significant oncogenic role across a broad spectrum of human malignancies. This review synthesizes current knowledge on the expression landscape, oncogenic functions, molecular mechanisms, and clinical significance of ERCC6L in cancer. Pan-cancer analyses consistently demonstrate that ERCC6L is frequently overexpressed in most tumor types compared to normal tissues, driven by mechanisms such as DNA amplification and promoter hypomethylation. This upregulation strongly correlates with aggressive clinicopathological features, including advanced tumor stage, metastasis, and poor patient prognosis across cancers like breast cancer, hepatocellular carcinoma, lung adenocarcinoma, and gastric cancer. Functionally, ERCC6L acts as a potent driver of malignant phenotypes by promoting uncontrolled proliferation through cell cycle acceleration, exerting anti-apoptotic effects, and enhancing invasion and metastasis via epithelial-mesenchymal transition. Mechanistically, ERCC6L operates at the nexus of multiple cancer pathways. It interacts with key mitotic regulators including PLK1, FOXM1, and KIF4A to govern cell cycle progression, activates pro-survival signaling cascades such as PI3K/AKT and NF-κB, and drives metastasis via PJA2-mediated p53 ubiquitination in lung adenocarcinoma. Furthermore, ERCC6L promotes metabolic reprogramming by stabilizing HIF-1α or transactivating PLK1 to drive aerobic glycolysis, and modulates DNA damage response, linking it to radio- and chemoresistance. Emerging evidence also connects ERCC6L to an immunosuppressive tumor microenvironment, with associations including Th2 cell infiltration, macrophage polarization, and reduced immune infiltration in HRD-high tumors, suggesting potential as a predictive biomarker for immunotherapy. The consistent association with aggressive tumor behavior positions ERCC6L as a valuable prognostic biomarker and a promising therapeutic target. Preclinical studies demonstrate that ERCC6L inhibition suppresses tumor growth and enhances treatment efficacy; however, current evidence is limited to
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.